Delivery of BioNTech SE and Pfizer’s shot to combat the omicron COVID-19 variant is set to be delayed by several weeks due to slower than expected data collecting process, BioNTech CEO Ugur Sahin reported to Germany’s Bild.
CEO Sahin added that the firm would assess whether the vaccine was still needed once the vaccine was ready.
He said that if the wave ends, that does not mean it cannot begin again, noting that the German pharma-makers can design new vaccines if needed as variants emerge. CEO Sahin argued that he doesn’t really see the situation as dramatic anymore, citing the potential behavior of the virus in the future.
BioNTech has previously targeted the vaccine launch by the end of March. In January, the firm and its U.S. partner Pfizer announced that the dosing had started in their test for the Omicron-based vaccine candidate.
Comments of the BioNTech CEO, Ugur Sahin, come when the new COVID-19 cases are on the decline across the globe. In January 2022, vaccine manufacturers sold off after some U.S. health officials questioned the rush to develop Omicron-specific vaccines.
Late in 2021, BioNTech and Pfizer announced lab-based findings to indicate the three shots of their COVID-19 vaccine neutralized the Omicron variant, while two doses led to considerably reduced neutralization titers.